Can Polycythemia Increase Your Risk of Blood Clots?

By Staff Writer Last Updated January 29, 2026

Polycythemia describes a condition in which the body has an abnormally high concentration of red blood cells. That increase can thicken blood and, in some forms of polycythemia, raise the likelihood of forming harmful clots in arteries or veins. This article explains how polycythemia can affect clotting risk, what factors matter most, current management approaches intended to lower that risk, and practical steps patients and caregivers can discuss with clinicians.

How polycythemia is defined and why it matters

In clinical practice, polycythemia is identified by elevated hemoglobin, hematocrit, or measured red-cell mass. Two broad categories are commonly used: primary polycythemia (most famously polycythemia vera, a myeloproliferative neoplasm driven in most cases by a JAK2 gene mutation) and secondary polycythemia (an appropriate increase in red cells in response to low oxygen, certain medications, or other drives). The consequence shared across types is increased red-cell mass and, frequently, higher blood viscosity — a physiologic change that can slow flow and support clot formation when other risk factors are present.

Key components that determine clot risk

Not all polycythemia carries the same clot risk. Important, evidence-backed drivers of thrombotic (clotting) risk include: older age (commonly defined as ≥60 years in many studies), a prior history of arterial or venous thrombosis, an elevated hematocrit (the proportion of blood made up by red cells), and additional blood-count abnormalities such as leukocytosis. Coexisting cardiovascular risk factors — hypertension, diabetes, smoking, high cholesterol, and obesity — also raise the probability that a clot will cause a major event like a heart attack or stroke.

Why polycythemia vera (PV) differs from secondary polycythemia

Polycythemia vera (PV) is a clonal bone-marrow disorder that commonly produces excess red cells and often elevated platelets or white cells; PV is consistently associated with an increased risk of both arterial and venous thrombosis. By contrast, most cases of secondary polycythemia (for example due to smoking, sleep apnea, or living at high altitude) do not show the same degree of laboratory markers of coagulation activation and are generally associated with a lower, though not zero, thrombosis risk. Treatment approaches and risk mitigation therefore differ between PV and secondary causes.

Benefits and clinical considerations in reducing clot risk

Randomized trials and guideline reviews have established practical targets and therapies aimed at lowering thrombotic complications in PV. Two widely used measures shown to reduce risk are: maintaining a hematocrit below a defined target (commonly

Recent trends and evolving practice (context as of January 20, 2026)

Guideline-driven care has increasingly emphasized strict hematocrit control and comprehensive cardiovascular risk management for PV patients. Clinical trials and large registry analyses continue to clarify additional risk markers — for example, the role of persistent leukocytosis and disease symptoms in predicting events — and to refine when to introduce disease-modifying medications. Research on molecular-targeted therapies and the long-term effects of newer treatments is active, and specialist hematology centers increasingly provide multidisciplinary care focused on both clot prevention and quality of life.

Practical steps patients and clinicians commonly take

If you or someone you care for has elevated red-cell counts, practical, evidence-aligned actions typically include: confirming the diagnosis (distinguish PV from secondary causes using history, oxygenation status, erythropoietin levels, and targeted mutation testing), regular monitoring of hematocrit and full blood counts, and a risk-based prevention plan. For many PV patients this plan combines routine phlebotomy (to lower hematocrit), low-dose aspirin when safe, and blood-count–lowering medication for higher-risk patients. Equally important are lifestyle measures to lower cardiovascular risk — smoking cessation, blood pressure control, cholesterol management, weight optimization, and safe exercise — which help reduce the chance that a clot will produce a major event.

Table: Comparing typical features, clot risk, and management (overview)

Feature	Primary polycythemia (PV)	Secondary polycythemia
Typical cause	Clonal bone marrow disorder (often JAK2 mutation)	Physiologic response to low oxygen, EPO-producing tumors, drugs, or smoking
Usual clot risk	Markedly elevated risk for arterial and venous thrombosis	Generally lower thrombotic activation; risk varies with comorbidities
Common preventive steps	Hematocrit control (target	Treat underlying cause; manage cardiovascular risks; consider phlebotomy selectively
When to see a specialist	At diagnosis and for ongoing hematology follow-up	If cause unclear, hematocrit very high, or thrombotic events occur

Important safety notes and practical tips for everyday life

Always discuss clot-prevention strategies with your treating clinician before starting or stopping any medication. Some commonly suggested practical tips patients can discuss with their care team include: keep scheduled blood tests to monitor hematocrit; ask whether low‑dose aspirin is appropriate for you; follow advice about phlebotomy scheduling if that is part of your plan; treat sleep apnea and other reversible causes of low oxygen; manage cardiovascular risk factors aggressively; and avoid dehydration or prolonged immobility when possible (for example, consider mobility strategies during long travel). If you develop new focal neurologic symptoms, chest pain, shortness of breath, new limb swelling or severe unexplained pain, seek urgent evaluation because these can be signs of a serious clot.

Closing thoughts

Polycythemia can increase the risk of blood clots, but the size of that risk depends strongly on the underlying cause, blood-count features, age, prior thrombosis, and coexisting cardiovascular risks. For people with polycythemia vera, evidence-based measures such as maintaining a lower hematocrit target and using low‑dose aspirin when appropriate substantially reduce thrombotic events. Secondary polycythemia generally carries a different, often lower, risk profile, but individualized assessment and attention to reversible contributors are essential. Regular follow-up with a hematologist and coordinated management of heart and vascular risk factors provide the best path to lower the chance of a clot while preserving long-term health.

Frequently asked questions

Q: Does every person with polycythemia get blood clots?
No. Not everyone with elevated red cells will develop a clot. The overall risk depends on the specific diagnosis (PV versus secondary causes), patient age, prior clot history, hematocrit level, and other vascular risk factors.
Q: What hematocrit level is considered safer to prevent clots?
Clinical trials and guidelines commonly use a target hematocrit below 45% for many adults with polycythemia vera, because maintaining lower hematocrit has been associated with fewer major thrombotic events. Individual targets may vary by sex, age, and comorbid conditions and should be determined by a clinician.
Q: Can lifestyle changes lower clot risk if I have polycythemia?
Yes. Managing smoking, blood pressure, cholesterol, weight, and physical activity all reduce the chance that a clot will cause serious harm. Treating reversible causes of secondary polycythemia (such as sleep apnea) may also reduce red-cell counts and risk.
Q: When should I seek emergency care?
Seek urgent care for sudden, severe symptoms such as chest pain, shortness of breath, sudden weakness or speech changes, or sudden swelling and pain in a limb — these may indicate a blood clot and require prompt evaluation.

Sources

Medical disclaimer: This article provides general information about polycythemia and thrombosis risk and does not replace personalized medical advice. For diagnosis and treatment decisions, consult a qualified healthcare professional.

This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.